Chiesi

Chiesi ups its focus on rare diseases

https://pharmaphorum.com/r-d/views-analysis-r-d/chiesi-ups-its-focus-on-rare-diseases/

Chiesi starts rare diseases division, ahead of potential Fabry disease filing

https://pharmaphorum.com/news/chiesi-starts-rare-diseases-division-as-fabry-treatment/

FDA rejection scuppers AZ’s hopes of a COPD triple clash with GSK

https://pharmaphorum.com/news/fda-rejection-scuppers-azs-hopes-of-a-copd-triple-clash-with-gsk/

Verona to take COPD hopeful into phase 3

https://pharmaphorum.com/market-access-2/verona-to-take-copd-hopeful-into-phase-3/

Europe: thumbs up for Roche’s Hemlibra, Chiesi rare disease drug, bad news for Santhera

https://pharmaphorum.com/news/roches-haemophilia-drug-poised-hit-eu-market/

COPD triple approved, can GSK maximise its revenues?

https://pharmaphorum.com/news/gsk-launch-copd-triple-therapy-us/

Verona pushes on with COPD drug after £70m fundraiser

https://pharmaphorum.com/news/verona-copd-ipo/

Chiesi backs up COPD triple therapy with real world study

https://pharmaphorum.com/news/chiesi-looks-real-world-study-copd-contender/

European regulators back Chiesi COPD triple therapy

https://pharmaphorum.com/news/european-chiesi-copd-therapy/

Close in 10 seconds

Pharmaphorum.com

Search